Takahiro Kasamatsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takahiro Kasamatsu has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Naoya Murakami
Department of Radiation Oncology, Juntendo University Graduate School of Medicine , 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421
4 shared publications - Takashi Onda
Department of Gynecology, Kitasato University School of Medicine, Sagamihara, Japan
3 shared publications - Fumiaki Isohashi
Department of Radiation Oncology Nara Medical University Kashihara Nara Japan
2 shared publications - Hiroyuki Okamoto
Section of Radiation Safety and Quality Assurance, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
2 shared publications - Jun Itami
Division of BNCT, EPOC, National Cancer Center, Tokyo 104-0045, Japan
2 shared publications - Mitsuya Ishikawa
Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan
2 shared publications
Latest Publications
- Open Access
- 29 July 2019
- Published by Springer Nature in Radiation Oncology
- Vol. 14 (1) , 1-9
Dummy-run for standardizing plan quality of intensity-modulated radiotherapy for postoperative uterine cervical cancer: Japan Clinical Oncology Group study (JCOG1402)
The purpose of this study was to assess compliance with treatment planning in a dummy-run for a multicenter clinical trial involving patients with high-risk postoperative uterine cervical cancer using intensity-modulated radiation therapy (IMRT) (JCOG1402 trial). For the dummy-run, we prepared a computed tomography dataset comprising two anonymized cases of post-hysterectomy cervical cancer. These were sent to the 47 participating institutions to assess institutional plan quality such as delineations and dose distributions. Central review showed 3 and 4 deviations per treatment plan on average. The deviations related to the nodal and vaginal cuff clinical target volume (CTV) delineation, which accounted for approximately 50% of the total deviations. The CTV vaginal cuff showed considerable differences in delineation compared with the nodal CTV. For the Dice similarity coefficient, case 1 showed a mean ± 1σ of 0.81 ± 0.03 and 0.60 ± 0.09 for the nodal and the CTV vaginal cuff, respectively, while these were 0.81 ± 0.04 and 0.54 ± 0.14, respectively, for case two. Of the 47 institutions, 10 were required to resubmit their treatment plan because the delineations, planning target volume margin, and required dose distributions were not in accordance with the JCOG1402 protocol. The dummy-run test in postoperative uterine cervical cancer demonstrated substantial deviations in the delineations, particularly for the CTV vaginal cuff. The analysis data could provide helpful information on delineation and planning, allowing standardization of IMRT planning for postoperative uterine cervical cancer. Japanese Clinical Trial Registry #: UMIN000027017 at https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000030672;language=J
- 29 July 2019
- Published by Springer Nature in Radiation Oncology
- Vol. 14 (1) , 1-9
Open AccessDummy-run for standardizing plan quality of intensity-modulated radiotherapy for postoperative uterine cervical cancer: Japan Clinical Oncology Group study (JCOG1402)
The purpose of this study was to assess compliance with treatment planning in a dummy-run for a multicenter clinical trial involving patients with high-risk postoperative uterine cervical cancer using intensity-modulated radiation therapy (IMRT) (JCOG1402 trial). For the dummy-run, we prepared a computed tomography dataset comprising two anonymized cases of post-hysterectomy cervical cancer. These were sent to the 47 participating institutions to assess institutional plan quality such as delineations and dose distributions. Central review showed 3 and 4 deviations per treatment plan on average. The deviations related to the nodal and vaginal cuff clinical target volume (CTV) delineation, which accounted for approximately 50% of the total deviations. The CTV vaginal cuff showed considerable differences in delineation compared with the nodal CTV. For the Dice similarity coefficient, case 1 showed a mean ± 1σ of 0.81 ± 0.03 and 0.60 ± 0.09 for the nodal and the CTV vaginal cuff, respectively, while these were 0.81 ± 0.04 and 0.54 ± 0.14, respectively, for case two. Of the 47 institutions, 10 were required to resubmit their treatment plan because the delineations, planning target volume margin, and required dose distributions were not in accordance with the JCOG1402 protocol. The dummy-run test in postoperative uterine cervical cancer demonstrated substantial deviations in the delineations, particularly for the CTV vaginal cuff. The analysis data could provide helpful information on delineation and planning, allowing standardization of IMRT planning for postoperative uterine cervical cancer. Japanese Clinical Trial Registry #: UMIN000027017 at https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000030672;language=J
- Open Access
- 22 January 2019
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 45 (4) , 882-891
Identifying selection criteria for non‐radical hysterectomy in FIGO stage IB cervical cancer
Aim: This retrospective study sought to identify the selection criteria required for a non‐radical hysterectomy with minimal parametrectomy in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB invasive cervical cancer.Methods: Overall, 461 patients with FIGO stage IB cervical cancer who underwent a radical hysterectomy were reviewed clinicopathologically according to pathological tumor size (≤2 cm, >2 – ≤4 cm, and > 4 cm).Results: The pathological parametrial involvement rate in the less than equal to 2 cm group (2%) was significantly lower than in greater than 2–less than equal to 4 cm (13%) or greater than 4 cm (29%) groups (both P < 0.001). The 5‐year overall survival rate was significantly higher in the less than equal to 2 cm group (97%, 95% confidence interval [CI] 94–99%) compared with greater than 2–less than equal to 4 cm (90%, 95% CI 94–86%) and greater than 4 cm (70%, 95% CI 79–60%) groups (both P < 0.001). Cox model analysis identified tumor size to be an independent prognostic factor for survival (95% CI 1.33–5.78) and recurrence (95% CI 1.31–5.66) compared to other pathological factors. However, a significant difference between the three groups was not found in rates of Grade 3 or 4 adverse events following radical hysterectomy (P = 0.19).Conclusions: Tumor size is an independent prognostic factor for survival in patients with FIGO stage IB invasive cervical cancer. This retrospective study suggests that FIGO stage IB patients with a less than equal to 2 cm tumor size are optimal candidates for non‐radical hysterectomy with minimal parametrectomy, and without resulting bladder dysfunction.
- 22 January 2019
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 45 (4) , 882-891
Open AccessIdentifying selection criteria for non‐radical hysterectomy in FIGO stage IB cervical cancer
Aim: This retrospective study sought to identify the selection criteria required for a non‐radical hysterectomy with minimal parametrectomy in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB invasive cervical cancer.Methods: Overall, 461 patients with FIGO stage IB cervical cancer who underwent a radical hysterectomy were reviewed clinicopathologically according to pathological tumor size (≤2 cm, >2 – ≤4 cm, and > 4 cm).Results: The pathological parametrial involvement rate in the less than equal to 2 cm group (2%) was significantly lower than in greater than 2–less than equal to 4 cm (13%) or greater than 4 cm (29%) groups (both P < 0.001). The 5‐year overall survival rate was significantly higher in the less than equal to 2 cm group (97%, 95% confidence interval [CI] 94–99%) compared with greater than 2–less than equal to 4 cm (90%, 95% CI 94–86%) and greater than 4 cm (70%, 95% CI 79–60%) groups (both P < 0.001). Cox model analysis identified tumor size to be an independent prognostic factor for survival (95% CI 1.33–5.78) and recurrence (95% CI 1.31–5.66) compared to other pathological factors. However, a significant difference between the three groups was not found in rates of Grade 3 or 4 adverse events following radical hysterectomy (P = 0.19).Conclusions: Tumor size is an independent prognostic factor for survival in patients with FIGO stage IB invasive cervical cancer. This retrospective study suggests that FIGO stage IB patients with a less than equal to 2 cm tumor size are optimal candidates for non‐radical hysterectomy with minimal parametrectomy, and without resulting bladder dysfunction.
- Open Access
- 22 December 2018
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 24 (5) , 575-582
A multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors
The aim of this study was to evaluate the effects of treatment with both three-dimensional radiotherapy (3DRT) and weekly 40-mg/m2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors.
- 22 December 2018
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 24 (5) , 575-582
Open AccessA multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors
The aim of this study was to evaluate the effects of treatment with both three-dimensional radiotherapy (3DRT) and weekly 40-mg/m2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors.
- Open Access
- 2 November 2014
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 45 (1) , 123-126
Non-randomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer: Japan Clinical Oncology Group Study (JCOG1101)
A non-randomized confirmatory trial was started in Japan to evaluate the efficacy of modified radical hysterectomy in patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer, for which the current standard is radical hysterectomy. This study began in January 2013 and a total of 240 patients will be accrued from 37 institutions within 3 years. The primary endpoint is 5-year survival. The secondary endpoints are overall survival, relapse-free survival, local relapse-free survival, percent completion of modified radical hysterectomy, percent local relapse, percent pathological parametrial involvement, days until self-urination and residual urine disappearance, blood loss, operation time, percent post-operative radiation therapy, adverse events and severe adverse events. This trial was registered at the UMIN Clinical Trials Registry as UMIN 000009726 (http://www.umin.ac.jp/ctr/).
- 2 November 2014
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 45 (1) , 123-126
Open AccessNon-randomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer: Japan Clinical Oncology Group Study (JCOG1101)
A non-randomized confirmatory trial was started in Japan to evaluate the efficacy of modified radical hysterectomy in patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer, for which the current standard is radical hysterectomy. This study began in January 2013 and a total of 240 patients will be accrued from 37 institutions within 3 years. The primary endpoint is 5-year survival. The secondary endpoints are overall survival, relapse-free survival, local relapse-free survival, percent completion of modified radical hysterectomy, percent local relapse, percent pathological parametrial involvement, days until self-urination and residual urine disappearance, blood loss, operation time, percent post-operative radiation therapy, adverse events and severe adverse events. This trial was registered at the UMIN Clinical Trials Registry as UMIN 000009726 (http://www.umin.ac.jp/ctr/).
- 1 September 2014
- Vol. 34 (9) , 5091-8
A dosimetric analysis of intensity-modulated radiation therapy with bone marrow sparing for cervical cancer.
The purpose of the present study was to compare intensity-modulated radiation therapy (IMRT) plan with (Bone Marrow Sparing (BMS) - IMRT) or without (normal-IMRT) an intention of avoiding bone marrow in order to minimize treatment-related toxicity. Computed tomography (CT) images of 10 consecutive postoperative cervical cancer patients were used. All patients were already treated by normal-IMRT. BMS-IMRTs were created for this study and dose-volume histogram parameters were compared. Both planning target volume (PTV) D95% and D97% were statistically lower in BMS-IMRT than normal-IMRT, however, the difference was lower than 3%. There were no statistical differences between BMS-IMRT and normal-IMRT in the mean value of rectum V30Gy, V50Gy; bladder V45Gy, V50Gy; Bowel V35Gy, and V50Gy. Both in whole pelvic bone (WPB) and inner cavity of pelvic bone (ICPB), the mean value of V10Gy, V30Gy, and V40Gy of BMS-IMRT were statistically lower than that of normal-IMRT. Both lower and higher dose for WPB as well as ICPB were effectively lowered by BMS-IMRT.
- 1 September 2014
- Vol. 34 (9) , 5091-8
A dosimetric analysis of intensity-modulated radiation therapy with bone marrow sparing for cervical cancer.
The purpose of the present study was to compare intensity-modulated radiation therapy (IMRT) plan with (Bone Marrow Sparing (BMS) - IMRT) or without (normal-IMRT) an intention of avoiding bone marrow in order to minimize treatment-related toxicity. Computed tomography (CT) images of 10 consecutive postoperative cervical cancer patients were used. All patients were already treated by normal-IMRT. BMS-IMRTs were created for this study and dose-volume histogram parameters were compared. Both planning target volume (PTV) D95% and D97% were statistically lower in BMS-IMRT than normal-IMRT, however, the difference was lower than 3%. There were no statistical differences between BMS-IMRT and normal-IMRT in the mean value of rectum V30Gy, V50Gy; bladder V45Gy, V50Gy; Bowel V35Gy, and V50Gy. Both in whole pelvic bone (WPB) and inner cavity of pelvic bone (ICPB), the mean value of V10Gy, V30Gy, and V40Gy of BMS-IMRT were statistically lower than that of normal-IMRT. Both lower and higher dose for WPB as well as ICPB were effectively lowered by BMS-IMRT.
- Open Access
- 8 May 2012
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 38 (10) , 1260-1265
Combination of squamous cell carcinoma-antigen, carcinoembryonic antigen, and carbohydrate antigen 19-9 predicts positive pelvic lymph nodes and parametrial involvement in early stage squamous cell carcinoma of the uterine cervix
- 8 May 2012
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 38 (10) , 1260-1265
Open AccessCombination of squamous cell carcinoma-antigen, carcinoembryonic antigen, and carbohydrate antigen 19-9 predicts positive pelvic lymph nodes and parametrial involvement in early stage squamous cell carcinoma of the uterine cervix
- 15 April 2011
- Published by Wiley in Cancer Science
- Vol. 102 (5)
Novel virtual cytological analysis for the detection of endometrial cancer cells using autoscan fluoromicroscopy
- 15 April 2011
- Published by Wiley in Cancer Science
- Vol. 102 (5)
Novel virtual cytological analysis for the detection of endometrial cancer cells using autoscan fluoromicroscopy